Editorial
Human immunodeficiency virus-1 (HIV-1) is a retrovirus that causes reduction of CD4+ T cells by degrade of them. The restrictions of HIV-1 treatment such as Highly-Active Retroviral Therapy (HAART) are not eliminated completely, for example: Drug resistance, no eradication of virus and rebounding of its replication from latent reservoirs after stopping them [1] [2] [3] .But new approaches in HIV/AIDS therapy based on gene and cell therapies solved many problems of treatment for intractable disease [4] [5] [6] [7] . Some polymorphisms provide nature resistance to HIV-1 or slow progression to AIDS (acquired immune deficiency syndrome) such as HLA-B27 and B57 [8] and CCR5 mutations [9] . Cc-chemokine receptor-5 (CCR5) -known as a main co-receptor in HIV-1 infection-because homozygote 32bp deletion (Δ32) in both allele of CCR5 provide natural resistance to HIV-1 infection [10] [11] [12] . This resistance was applied in Berlin patient that transplanted by allogeneic hematopoietic stem cell (HSC)from a donor with CCR5 Δ32/Δ32genotype to HIV-1 infected patient and introduced effective cure in the absent of ART [13] [14] [15] [16] [17] . Afterwards, same strategy was exhibited satisfactory results for HIV-1 treatment in Boston patients [18] . Founding a suitable donor with low prevalence of target genotype (CCR5 Δ32/Δ32) and HLA-matched are main problems of HSCT strategies as allogeneic. latest finding indicates that autologous HSCT for m303/m303 could be effective treatment for anyone HIV/AIDS affected patient worldwide [19] . It is predicted that gene therapy for HIV-1 infection can apply easier and more accessible with respect to HSCT by umbilical cord blood (CB) [20, 21] . Next approaches -cell engineering-overcome to these challenges: disruption of target gene by special enzyme [22, 23] . It is showed that CCR5disruptin HIV-1 infected patient by ZFN and return modified stem cells to self-body as autologous stem cell transplantation [24] . Furthermore, another nuclease such as CRISPR/Cas9 (Clustered regularly interspaced palindromic repeats/CRISPR associated gene) could modify viral genome to inhibition of viral integration, gene expression and replication [25, 26] . It is demonstrated that CRISPR/ Cas9 edit CCR5gene efficacy in hematopoietic stem cells [27] . So, we can be said cell engineering with nucleases can eliminate some problems of Berlin and Boston patients. In this manner, gene therapy in HIV-1 infected patient could be more carefree. In other hand, to compare to current ART strategy, gene therapy can be cost effective in HIV infected patient lifetime [28] . So, novel strategies based on stem cell transplantation is better than retroviral drugs and they have significance positive effect in eradication or reduction of viral genome from HIV-1 infected patients. A better understanding of the host immunology and genetic factors that promote or restrict HIV-1 replication may thus lead to the development of novel therapeutics against HIV/AIDS in future.
Hopefully one day we'll be able to say all AIDS patients become HIV negative again. 
